Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 128

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 128
---
VIUM RX.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands, except share and per share data

NOTE 9 – SHAREHOLDERS’ EQUITY (Cont.)

Successor:

On February 9, 2024, the Predecessor Board of Directors approved the following:

| 1. | Amendment                                                                                          
 to the Company’s Global Share Incentive Plan (2021), increasing the number of shares               
 available for issuance under Company’s Global Share Incentive Plan (2021) to 20,000,000            
 (the “Plan Amendment”). The Plan Amendment became effective on the date of the                     
 approval by the Board of Directors, but it is subject to approval by the holders of a majority     
 of the voting power of the Company within 12 months, pursuant to section 422(b)(1) of the Internal 
 Revenue Code.                                                                                      |

On November 11, 2024, following discussions with the management of the Company, the Board has determined that it is advisable and in the best interests of the Company and its stockholders to further amend the Plan, as amended (“Amendment #2”), to reduce the maximum number of shares reserved for issuance under the Plan from 20,000,000 shares of Common Stock to 10,000,000 shares of Common Stock. Amendment No. 2 became effective on the date of approval by the Board of Directors, but it is subject to approval by the Company’s shareholders within 12 months, pursuant to section 422(b)(1) of the Internal Revenue Code

| 2. | A                                                                                                
 grant to the Predecessor Chief Executive Officer 3,800,000 stock options at an exercise price    
 of $0.001 per share. 1,900,000 options were fully vested upon grant and the remaining 1,900,000  
 options are scheduled to vest on a quarterly basis over two years in equal quarterly instalments 
 of 237,500 options, beginning with the quarter ended March 31, 2024. The options are exercisable 
 within eight years from grant date. The aggregate grant date fair value of such options was      
 approximately $4,770.                                                                            |

| 3. | A                                                                                                 
 grant to the Chairman of the Board 160,000 stock options at an exercise price of $0.40 per        
 share. 80,000 options were fully vested upon grant and the remaining